Synthesis and Antiviral Properties against SARS-CoV-2 of Epoxybenzooxocino[4,3-b]Pyridine Derivatives

The COVID-19 pandemic is ongoing as of mid-2022 and requires the development of new therapeutic drugs, because the existing clinically approved drugs are limited. In this work, seven derivatives of epoxybenzooxocinopyridine were synthesized and tested for the ability to inhibit the replication of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Stalinskaya, Alena L., Martynenko, Nadezhda V., Shulgau, Zarina T., Shustov, Alexandr V., Keyer, Viktoriya V., Kulakov, Ivan V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230803/
https://www.ncbi.nlm.nih.gov/pubmed/35744830
http://dx.doi.org/10.3390/molecules27123701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230803/
https://www.ncbi.nlm.nih.gov/pubmed/35744830
http://dx.doi.org/10.3390/molecules27123701

Ejemplares similares